This protocol addresses the management of Syndrome of inappropriate antidiuretic hormone secretion (SIADH) in patients where an initial trial of fluid restriction did not produce a clinically adequate rise in serum sodium. Pharmacological escalation is indicated in this setting.
Fluid restriction — limiting all discretionary fluid intake to 500 mL/d below the 24-hour urine volume, without restricting sodium or protein, and discontinuing drugs known to be associated with SIADH — was applied but did not achieve its required goals: a significant increase in plasma osmolality and a rise in serum sodium toward a stable value above 125 mmol/L, as reassessed at 24–48 hours. This failure of response, or inability to sustain the restriction, warrants escalation to pharmacological therapy.
When fluid restriction is ineffective, impractical, or unpalatable, pharmacological therapy is the indicated next step. Multiple distinct agents — available in both oral and intravenous formulations — can be employed, each targeting fluid and sodium balance through different mechanisms. Agent selection, titration approach, and the full sequenced regimen are available in the complete protocol.
DOI: 10.1016/j.amjmed.2013.07.006
In cases of SIADH where the cause of hyponatremia persists, and where fluid restriction is ineffective, impractical, or unpalatable, pharmacological therapy should be considered.
Because a 6-mmol/L increase appears to be sufficient for patients with the most severe manifestations of hyponatremia, we believe that the goal of therapy (ie, the desired increase in serum [Na⁺]) in chronic hyponatremia should be 4-8 mmol/L/d for those at low risk of ODS, with an even lower goal of 4-6 mmol/L/d if the risk of ODS is high.
Once the serum [Na⁺] has reached 125 mmol/L, the risk of CNS complications of hyponatremia is low.
View source ↗